Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.44 |
| ▸ | MTOR | P42345 | 3/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22200572 | 0.86 | ERN1 (0.40) | PIK3CAMTORBTKFGFR1FGFR2 | |
| SCHEMBL22200582 | 0.83 | PIK3CA (0.43) | PIK3CAMTORBTKFGFR1FGFR2 | |
| SCHEMBL25034132 | 0.83 | PIK3CA (0.45) | PIK3CAMTORFGFR1FGFR2FGFR4 | |
| SCHEMBL22200441 | 0.82 | PIK3CA (0.35) | PIK3CAMTORBTKFGFR1FGFR2 | |
| SCHEMBL22200562 | 0.82 | PIK3CA (0.42) | PIK3CAMTORBTKFGFR1FGFR2 | |
| SCHEMBL22200626 | 0.80 | ERN1 (0.41) | PIK3CAMTORFGFR1FGFR2FGFR4 | |
| SCHEMBL22200372 | 0.80 | PIK3CA (0.46) | PIK3CAMTORBTKFGFR1FGFR2 | |
| SCHEMBL22200817 | 0.78 | MTOR (0.40) | PIK3CAMTOR | |
| SCHEMBL22200363 | 0.77 | EGFR (0.46) | PIK3CAMTORBTKFGFR1FGFR2 | |
| SCHEMBL22200749 | 0.77 | PIK3CA (0.56) | PIK3CAMTORFGFR1FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |